• Bone loss (osteoporosis) and spinal fractures are serious side effects of this therapy. (cochrane.org)
  • an absolute benefit of 2% fewer people (5% fewer to 1% more) sustaining spinal fractures when taking bisphosphonates. (cochrane.org)
  • Approximately 31 people (range 20 to 145) would need to be treated with bisphosphonates to prevent spinal fractures in one person. (cochrane.org)
  • Based on moderate- to high-certainty evidence, we found that bisphosphonates are beneficial in preventing new spinal fractures and preventing and treating steroid-induced bone loss at the lumbar spine and femoral neck. (cochrane.org)
  • For preventing non-spinal fractures, we found that there was little or no difference whether patients used bisphosphonates or not, although this evidence was low-certainty because the methods used to assess non-spinal fractures were subject to bias. (cochrane.org)
  • Overall, our review supports the use of bisphosphonates to reduce the risk of spinal fractures and in the prevention and treatment of steroid-induced bone loss. (cochrane.org)
  • There was high-certainty evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures with data extending to 24 months of use. (cochrane.org)
  • A clinical practice guideline from the American College of Physicians on treatment to prevent fractures in men and women with low bone density or osteoporosis includes six recommendations: two strong recommendations, based on high- or moderate-quality evidence, and four weak ones, based on low-quality evidence. (medscape.com)
  • [ 147 ] In addition, a physician reminder in conjunction with a patient risk assessment strategy can result in a reduction in patient fractures and an increase in osteoporosis therapy. (medscape.com)
  • A 2009 study indicated that the use of a case manager for the treatment of patients with hip fractures can lead to more frequent use of appropriate osteoporosis treatment and may result in fewer fractures, increased life expectancy, and significant health-care cost savings. (medscape.com)
  • While several bone measurement tests similarly predict risk of fracture, DXA directly measures bone mineral density (BMD), and most treatment guidelines use central DXA to define osteoporosis and the treatment threshold to prevent osteoporotic fractures. (uspreventiveservicestaskforce.org)
  • The USPSTF found adequate evidence that clinical risk assessment tools are moderately accurate in identifying risk of osteoporosis and osteoporotic fractures. (uspreventiveservicestaskforce.org)
  • Studies show that drug therapies reduce fractures in postmenopausal women with osteoporosis. (uspreventiveservicestaskforce.org)
  • The USPSTF found convincing evidence that screening can detect osteoporosis and that treatment of women with osteoporosis can provide at least a moderate benefit in preventing fractures in women age 65 years and older. (uspreventiveservicestaskforce.org)
  • The USPSTF found adequate evidence that screening can detect osteoporosis and that treatment provides a moderate benefit in preventing fractures in postmenopausal women younger than age 65 years who are at increased risk of osteoporosis. (uspreventiveservicestaskforce.org)
  • The USPSTF found inadequate evidence on the benefits and harms of treating screen-detected osteoporosis to reduce the risk of osteoporotic fractures in men. (uspreventiveservicestaskforce.org)
  • Current evidence suggests that increasing the duration of bisphosphonate therapy longer than 3-5 years reduced the risk of new vertebral fractures but not the risk of other fractures. (meefro.com)
  • The guideline also suggests that clinicians use the RANK ligand inhibitor (denosumab) as a second-line pharmacologic treatment to reduce the risk of fractures in postmenopausal females and males diagnosed with primary osteoporosis who have contraindications to or experience adverse effects of bisphosphonates. (meefro.com)
  • ACP suggests that clinicians use the sclerostin inhibitor (romosozumab) or recombinant PTH (teriparatide), followed by a bisphosphonate, to reduce the risk of fractures only in females with primary osteoporosis with a very high risk of fracture. (meefro.com)
  • Take a bisphosphonate to lower the risk of bone fractures. (networkofcare.org)
  • Osteoporosis lawsuits regarding Fosamax, Actonel , Boniva, Zometa and Aredia allege femur fractures, jaw bone death and more. (freeadvice.com)
  • Litigation on osteoporosis femur fractures continues - especially after an ABC news program revealed the serious risks associated with these osteoporosis drugs known as subtrochateric femur fractures. (freeadvice.com)
  • Patients who use bisphosphonate drugs such as Fosamax , Actonel, Boniva, Zometa, and Aredia and have been on these drugs for prolonged periods of time - between three and five years - are suffering low energy femur fractures. (freeadvice.com)
  • In addition to subtrochateric femur fractures, long-term exposure to bisphosphonate drugs also increases the probability of developing osteonecrosis of the jaw (ONJ - also known as avascular necrosis, aseptic necrosis, ischemic necrosis or jaw bone death. (freeadvice.com)
  • ABSTRACT Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis and reduce fragility fractures. (bvsalud.org)
  • Around the world, every three seconds a bone fractures owing to osteoporosis. (saga.co.uk)
  • In the UK, more than three million people now have osteoporosis, with more than a quarter of a million fractures each year, and treating it is estimated to cost the NHS up to £2 billion a year. (saga.co.uk)
  • The trauma that causes fractures in older people with osteoporosis can be quite mild - falling out of bed, tripping over, and so on,' he says. (saga.co.uk)
  • This happens to almost everyone, but it becomes osteoporosis only when the bones become fragile and vulnerable to fractures. (saga.co.uk)
  • The occurrence of fragility fractures and the finding of low bone mineral density (BMD) help to diagnose osteoporosis. (aafp.org)
  • This ACP guideline on treatment of low BMD or osteoporosis to prevent fractures describes the available evidence on pharmacologic treatment in men and women. (aafp.org)
  • Physicians should offer pharmacologic treatment to men and women with osteoporosis or fragility fractures. (aafp.org)
  • It is important to find osteoporosis early to help prevent fractures. (cancer.ca)
  • Background: Osteoporosis is a debilitating disease characterized by bone micro-architecture degradation contributing to fragility fractures. (eurekaselect.com)
  • Bisphosphonates deactivate those cells used to break down bone and therefore prevent fractures caused by brittleness of the bone. (sciencedaily.com)
  • Although, for some time, there have been doubts that bisphosphonates can be the cause of other forms of fractures such as fatigue fractures, by virtue of the fact that they also inhibit natural degradation of bone. (sciencedaily.com)
  • Of these 59 patients, 78 % had been administered with bisphosphonates whereas only 5% of all forms of fractures within the general population had received the same treatment. (sciencedaily.com)
  • The connection between the bisphosphonates and the fractures is so strong they we propose that a causal connection can be confirmed. (sciencedaily.com)
  • However, this study also indicates that the risk of fatigue fractures diminishes once a patient ceases to be administered bisphosphonates. (sciencedaily.com)
  • The principal effects of bisphosphonates remain: They significantly reduce the risk of fractures at the onset of osteoporosis. (sciencedaily.com)
  • Bisphosphonates prevent many more fractures than they cause. (sciencedaily.com)
  • May 5, 2021 Current guidelines for managing osteoporosis specifically call out hip or spine fractures for increasing the risk for subsequent bone breaks. (sciencedaily.com)
  • 11, 2020 Osteoporosis is characterized by a deterioration of the bones and an increased risk of fractures. (sciencedaily.com)
  • At this time, FDA believes that the benefits of oral bisphosphonate drugs in reducing the risk of serious fractures in people with osteoporosis continue to outweigh their potential risks. (rxwiki.com)
  • In a large cohort of Danish patients with fractures, investigators found that bisphosphonate users (who had taken them for a median of 1.5 years) had a significantly reduced risk for esophageal cancer compared to patients with fractures who had not taken any bisphosphonate. (rxwiki.com)
  • The study authors noted that their study was not powered to assess the risk of fractures during drug holidays, but they concluded that neither the type of bisphosphonate nor the duration of drug holiday significantly affected bone mineral density. (thedoctorschannel.com)
  • Anyone who takes glucocorticoid medications for more than three months is at risk of developing osteoporosis and fractures. (the-rheumatologist.org)
  • The most dangerous consequence of glucocorticoid-induced osteoporosis is fracture-including spine and hip fractures, which can lead to chronic pain, long-term disability, and death. (the-rheumatologist.org)
  • According to patient fact-sheet writer Shreyasee Amin, MD, "the major goal in the management of glucocorticoid-induced osteoporosis is the prevention of fractures and to help decrease bone loss. (the-rheumatologist.org)
  • Finally, it is important to remind patients that the major goal in the management of their glucocorticoid-induced osteoporosis is the prevention of fractures, and it is important to help prevent trauma, which can increase the risk for fractures. (the-rheumatologist.org)
  • Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective. (the-rheumatologist.org)
  • ACR CONVERGENCE 2020-Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday? (the-rheumatologist.org)
  • Osteoporosis develops as a result of decreased bone mass and density, and can lead to fractures. (healthline.com)
  • Since osteoporosis does not usually have obvious symptoms early on, screening and timely diagnosis are important to help prevent related bone fractures. (healthline.com)
  • Fractures from osteoporosis may occur spontaneously or from seemingly minor accidents and falls. (healthline.com)
  • Osteoporosis can lead to broken bones (fractures) in the hip, spine, and wrist. (healthlinkbc.ca)
  • By making bones stronger, alendronate can help to reduce the incidence of osteoporosis-related fractures. (medbroadcast.com)
  • As osteoporosis expert Lara Pizzorno explains, bisphosphonate drugs help prevent fractures in the short-term by suppressing osteoclasts, the cells that remove injured and damaged bone. (anh-usa.org)
  • With short-term use, they are shown to reduce the incidence of new fractures in patients with established osteoporosis. (holtorfmed.com)
  • In women with osteopenia, bisphosphonates are shown to prevent bone loss, and physicians prescribe them with the hope of preventing future fractures. (holtorfmed.com)
  • Some bisphosphonates (alendronate, risedronate, and zoledronic acid) prevent hip and other nonvertebral fractures. (medscape.com)
  • Alendronate (sold under various names, including Fosamax), risedronate (sold under names including Actonel) and ibandronate (Boniva) are all bisphosphonates that are taken orally. (everydayhealth.com)
  • Therapy includes antiresorptive agents such as bisphosphonates (eg, alendronate, risedronate, pamidronate, zoledronic acid) as well as calcium and vitamin D supplementation. (medscape.com)
  • Alendronate is an orally administered bisphosphonate that is approved as an antiresorptive agent to treat Paget disease and postmenopausal osteoporosis. (medscape.com)
  • To assess the relative efficacy of bisphosphonates (alendronate, risedronate, ibandronate and zoledronic acid) for the treatment of osteoporosis using network meta-analysis (NMA). (nih.gov)
  • A 66-year-old woman who began treatment with alendronate 6 months ago for osteoporosis presents to your office for medical clearance prior to dental work. (medscape.com)
  • Osteoporosis is a disease that causes bones to become brittle and more likely to fracture (break). (medlineplus.gov)
  • A bone density test shows you have osteoporosis, even if you have not had a fracture before, but your fracture risk is high. (medlineplus.gov)
  • You have a bone fracture, and a bone density test shows you have thinner than normal bones, but not osteoporosis. (medlineplus.gov)
  • Osteoporosis is common and the risk of fracture is high among patients who have undergone solid organ transplantation. (medscape.com)
  • Monitoring of bone mineral density (BMD) during the 5 years of treatment in women with osteoporosis is not advised, as evidence suggests that fracture risk may be reduced regardless of BMD changes. (medscape.com)
  • The USPSTF found no studies that evaluated the effect of screening for osteoporosis on fracture rates or fracture-related morbidity or mortality. (uspreventiveservicestaskforce.org)
  • Osteoporosis is a systemic skeletal disease characterized by decreasing bone mass and deterioration of bone tissue that leads to an increased risk for bone fragility and fracture, especially in the hip, spine, and wrist. (meefro.com)
  • Evenity offers a new osteoporosis treatment for post-menopausal women at high risk of bone fracture. (everydayhealth.com)
  • Deciding on a drug therapy to prevent fracture in osteoporosis has been an either/or proposition for doctors. (everydayhealth.com)
  • It's intended for women with a history of osteoporotic fracture or multiple risk factors for fracture, or for women who haven't responded to or are intolerant of other osteoporosis therapies . (everydayhealth.com)
  • More than 10 million people in the United States have osteoporosis, and an additional 44 million have low bone density , which places them at increased risk of fracture, according to the National Osteoporosis Foundation . (everydayhealth.com)
  • In our patients with osteoporosis who are at risk for fracture, we mostly use the types of drugs that stop your bones from breaking down," says Moseley. (everydayhealth.com)
  • You have osteoporosis or have had a fracture in your hip or spine. (networkofcare.org)
  • The decision about whether or not to take bisphosphonates depends on what your risk of a fracture is and how you feel about the pros and cons of your options. (networkofcare.org)
  • If you are at a higher risk of having a fracture, taking bisphosphonates is more likely to help you prevent a fracture. (networkofcare.org)
  • Not everyone with low bone density gets osteoporosis or has a fracture. (networkofcare.org)
  • Bisphosphonates are the most common medicines used to prevent bone loss in people who have osteoporosis or have a high risk of a fracture. (networkofcare.org)
  • And one in three women and one in five men aged over 50 will suffer an osteoporosis-related fracture, according to the International Osteoporosis Foundation. (saga.co.uk)
  • There is good evidence to support treating persons with osteoporosis to prevent continued bone loss and reduce the risk of fracture. (aafp.org)
  • Evidence has shown that bisphosphonates are a reasonable first-line treatment option, especially in persons at high risk of hip fracture. (aafp.org)
  • Patients with T-scores of -2.5 or lower are considered to have osteoporosis and are at a higher risk for a fracture. (the-rheumatologist.org)
  • Vancouver, British Columbia - A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among treatment-naive postmenopausal women with osteoporosis. (medscape.com)
  • Osteoporosis Canada also recommends that you and your doctor check your fracture risk using a tool such as CAROC (Canadian Association of Radiologists and Osteoporosis Canada) Risk Assessment or FRAX (Fracture Risk Assessment) starting at age 50. (healthlinkbc.ca)
  • Bisphosphonate drugs are used for treatment of osteoporosis, a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in post-menopausal women. (anh-usa.org)
  • Bone brittleness and fracture risk increase with increasing duration of bisphosphonate use even if bone density continually improves. (holtorfmed.com)
  • The diagnosis of osteoporosis should be based on bone density or a clinical history that includes low-trauma fracture. (medscape.com)
  • Zoledronic acid (sold as Zometa and Reclast) is also a bisphosphonate, given as an infusion through a vein in your arm once a year. (everydayhealth.com)
  • During the Q&A session after the talk, one audience member commented that the study was limited because the researchers only followed patients who received zoledronic acid for 60 days, which could have missed potential long-term benefits of the drug, especially since bisphosphonates have a lengthy skeletal retention time. (medscape.com)
  • An article and an accompanying letter to the editor in the May 3, 2007, issue of The New England Journal of Medicine describe increased rates of serious atrial fibrillation (defined by the authors as life-threatening or resulting in hospitalization or disability) in two different studies of older women with osteoporosis treated with the bisphosphonates, Reclast and Fosamax. (drug-injury.com)
  • Bisphosphonates such as Fosamax, Acetenol, Reclast, and Boniva are widely used to treat osteoporosis. (holtorfmed.com)
  • This includes a large study of 1700 women published in Archives of Internal Medicine that demonstrated that current and past users of bisphosphonate medication such as Fosamax, Actonel, Reclast, and Boniva had significantly increased risk of potentially fatal heart arrhythmias. (holtorfmed.com)
  • A total of 106 postmenopausal women with osteoporosis (mean age 70.8 years) were randomly divided into two groups (n=53 in each group): a bisphosphonate group (control group) and a bisphosphonate plus ED group (ED group). (scienceopen.com)
  • Be assured that we will continue to follow and report developments concerning the safety of Fosamax and the other bisphosphonate drugs going forward. (drug-injury.com)
  • This is reason to avoid Fosamax type drugs (with bisphosphonate), especially pre-menopause. (anh-usa.org)
  • Confused and concerned about calcium, bone health and osteoporosis medications like Fosamax, Prolia and Boniva? (mainlinetoday.com)
  • With osteoporosis, the bones lose density. (medlineplus.gov)
  • People with osteoporosis could either take a medication to slow down bone loss or take one that helps build bones. (everydayhealth.com)
  • Prolia (denosumab) is a human monoclonal antibody that treats osteoporosis by inhibiting the maturation of osteoclasts, which protects bones from degrading and slows the progression of the disease. (everydayhealth.com)
  • Osteoporosis is a disease that affects your bones . (networkofcare.org)
  • However, if you have established osteoporosis, lifestyle measures alone will not usually be enough to strengthen bones, and you may need treatment with medicines. (mydr.com.au)
  • Osteoporosis is a disease of the bones that causes bones to become weak and break easily. (womenshealth.gov)
  • Broken bones from osteoporosis cause serious health problems and disability in older women. (womenshealth.gov)
  • Osteoporosis is a disease of the bones. (womenshealth.gov)
  • People with osteoporosis have bones that are weak and break easily. (womenshealth.gov)
  • Roger Dobson suggests food and drinks that may help to protect bones, and examines the conventional treatments for osteoporosis. (saga.co.uk)
  • Osteoporosis is a condition in which bones lose mass, or density, and the bone tissue breaks down. (cancer.ca)
  • The bones that have the highest risk of breaking because of osteoporosis include those in the hip, pelvis, spine, ribs, wrist and leg. (cancer.ca)
  • But certain cancer types and treatments can also weaken bones, resulting in osteoporosis. (cancer.ca)
  • Osteoporosis can be caused by bone cancer or by certain types of cancer that spread to the bones, such as breast cancer, prostate cancer, lung cancer and multiple myeloma. (cancer.ca)
  • Bisphosphonates are drugs that strengthen bones and stop the natural process in which the body breaks down bone. (cancer.ca)
  • Arthritis and osteoporosis are both chronic, long-term conditions that affect your bones. (healthline.com)
  • Arthritis and osteoporosis both affect your bones, but they do not develop or present in the same way. (healthline.com)
  • An FDA-Approved Treatment for Osteoporosis that Actually Makes Bones Worse! (anh-usa.org)
  • FDA's prescription for bone health and osteoporosis has been shown to make bones far more fragile in the long term, and may even cause jaw death and esophageal cancer. (anh-usa.org)
  • In her excellent book Your Bones: How You Can Prevent Osteoporosis & Have Strong Bones for Life-Naturally (co-authored with our friend Jonathan V. Wright, MD), Pizzorno discusses natural integrative approaches to preventing osteoporosis and maintaining healthy bones that can be used over a lifetime. (anh-usa.org)
  • The brittle bones caused by bisphosphonates use is not limited to the jaw. (holtorfmed.com)
  • Osteoporosis is a condition that weakens your bones. (msdmanuals.com)
  • If you have osteoporosis, your bones break more easily. (msdmanuals.com)
  • When osteoporosis causes your bones to break, you usually have pain. (msdmanuals.com)
  • If you take bisphosphonates, calcium supplements should be taken several hours apart from the bisphosphonates. (mydr.com.au)
  • Harms of drug therapies for osteoporosis depend on the specific medication used. (uspreventiveservicestaskforce.org)
  • The USPSTF found that the risk of serious adverse events, upper gastrointestinal events, or cardiovascular events associated with the most common class of osteoporosis medication (bisphosphonates) is no greater than small. (uspreventiveservicestaskforce.org)
  • If you have osteoporosis, your doctor may prescribe medication for you or suggest you take certain supplements . (healthline.com)
  • Objective: This review highlights various established bone turnover markers that have found utility in the clinic as reliable and standardized indicators of bone turnover, with attention to those used to assess efficacy of bisphosphonate drug therapy - particularly in monitoring medication adherence in patients with postmenopausal osteoporosis. (eurekaselect.com)
  • Bisphosphonates are a common medication used to combat osteoporosis. (sciencedaily.com)
  • Bisphosphonates are a medication that has been administered since the 1990s, which reduces the overall risk of brittleness and incidence of osteoporosis. (sciencedaily.com)
  • This may indicate that one should seldom administer bisphosphonates and that the medication should be concluded after several years' treatment. (sciencedaily.com)
  • However he emphasises the fact that the benefits from bisphosphonate medication greatly exceed the negatives. (sciencedaily.com)
  • But we no longer suggest that everyone with osteopenia goes on osteoporosis medication. (mainlinetoday.com)
  • Osteoporosis patients who received bisphosphonates showed a higher incidence of AF occurrence than those that were not treated with bisphosphonates (P = .015). (tmu.edu.tw)
  • thus, the incidence was significantly lower than that in the patients treated with bisphosphonates (P = .007). (tmu.edu.tw)
  • In addition, the patients who were treated with vitamin D had a lower incidence of AF than did those who were not treated with either vitamin D or bisphosphonates (P = .074). (tmu.edu.tw)
  • The authors concluded that multicomponent tools aimed at doctors and patients may support clinical decision making in the management of osteoporosis. (medscape.com)
  • Our objective was to determine the benefits and harms of bisphosphonates for adults on long-term steroid therapy. (cochrane.org)
  • A thorough history and assessment of pre-existing systemic problems and possible sites of dental infection are required to help prevent the condition, especially if bisphosphonate therapy is considered. (wikipedia.org)
  • Hormone replacement therapy (HRT) was once widely used for women, but it has been linked to a risk of stroke and breast cancer and, according to the NHS, is almost never used to treat osteoporosis these days. (saga.co.uk)
  • Hormonal replacement therapy (HRT) and osteoporosis. (epnet.com)
  • Results: We posit that the use of urinary bone turnover markers values determined by immunoassay or ELISA at routine clinic visits might serve as valuable feedback to healthcare professionals and patients to help monitor the efficacy and adherence of bisphosphonate therapy and disease progression. (eurekaselect.com)
  • An FDA advisory committee now wants the FDA to limit how long a patient may be on bisphosphonate therapy, but committee members cannot agree on an appropriate time limit . (anh-usa.org)
  • Any treatment that cannot be used in the long term is a waste of time, money, and in the case of bisphosphonate therapy, dangerous as well. (anh-usa.org)
  • The possible risk from lower oral doses of bisphosphonates, taken by patients to prevent or treat osteoporosis, remains uncertain. (wikipedia.org)
  • Current treatments for osteoporosis involve the administration of high doses of bisphosphonates (BPs) over a number of years. (scilifelab.se)
  • Bisphosphonates are considered a first-line treatment for osteoporosis and have been used since the 1990s. (cochrane.org)
  • People were randomly assigned to receive either bisphosphonate treatment (alone or with calcium or vitamin D, or both) or 'no treatment' (given calcium or vitamin D or a placebo). (cochrane.org)
  • We found that the BMD of the lumbar spine of people taking bisphosphonates was 3.50% higher (2.90% to 4.10% higher) than in people who had no treatment. (cochrane.org)
  • We found that the BMD of the femoral neck was 2.06% higher in the bisphosphonate group (1.45% to 2.68% more) than in people with no treatment. (cochrane.org)
  • We found that there was little or no difference in the number of serious adverse events or withdrawals due to adverse events when comparing bisphosphonates to no treatment. (cochrane.org)
  • In postmenopausal women, estrogen or estrogen plus progestogen or raloxifene should not be used for the treatment of osteoporosis. (medscape.com)
  • Currently, no treatment can completely reverse established osteoporosis. (medscape.com)
  • If secondary osteoporosis is present, treatment for the primary disorder should be provided. (medscape.com)
  • Therefore, clinicians should consider stopping bisphosphonates after five years of treatment unless there is a strong indication to continue treatment. (meefro.com)
  • Evenity (romosozumab) is indicated for the treatment of osteoporosis in post-menopausal women at high risk of breaking a bone. (everydayhealth.com)
  • It is indicated for the prevention and treatment of osteoporosis. (medscape.com)
  • Osteoporosis treatment improves bone strength and reduces your chances of breaking a bone. (mydr.com.au)
  • Treatment choice is based on your age, sex and medical history, as well as how severe your osteoporosis is and the likelihood of you fracturing (breaking) a bone. (mydr.com.au)
  • Your doctor may refer you to a specialist endocrinologist , rheumatologist or specialist bone centre for osteoporosis treatment. (mydr.com.au)
  • Bisphosphonate-functionalized hyaluronic acid showing selective affinity for osteoclasts as a potential treatment for osteoporosis. (scilifelab.se)
  • The optimal duration of treatment is unclear, but studies on bisphosphonates have lasted three to 60 months. (aafp.org)
  • Physicians should consider pharmacologic treatment for men and women at risk of osteoporosis. (aafp.org)
  • Persons at risk of osteoporosis, but who do not have a T-score lower than −2.5 should be given treatment. (aafp.org)
  • Data supporting preventive treatment are stronger for persons at moderate risk of osteoporosis (i.e., persons with a T-score of −1.5 to −2.5, those receiving glucocorticoids, or those older than 62 years). (aafp.org)
  • Osteoporosis can be a side effect of hormone therapies used to treat breast, uterine, ovarian and prostate cancers because this treatment blocks or lowers the body's production of these hormones. (cancer.ca)
  • Kaplan-Meier analysis also showed a significant difference in AF occurrence in different groups during the 5-year follow-up (P = .010).Different treatment for osteoporosis may carry diverse risks of AF occurrence. (tmu.edu.tw)
  • Calcium and vitamin D for treatment and prevention of osteoporosis. (epnet.com)
  • Currently, determining bone mineral density (BMD) via dual-energy X-ray absorptiometry (DXA) is the most reliable form of diagnosing osteoporosis and managing pharmacological treatment regimens. (eurekaselect.com)
  • Commonly used for the prevention and treatment of osteoporosis as well as to treat other bone diseases such as Paget's disease. (rxwiki.com)
  • June 12, 2006 (Atlanta) - Women with breast cancer who are treated with the aromatase inhibitor anastrozole ( Arimidex , AstraZeneca) for 5 years can lose 6% to 7% in bone-mineral density (BMD), enough to trigger a progression to osteoporosis in those who are already osteopenic when treatment begins, according to a group of investigators that reported these findings here at the 42nd annual meeting of the American Society of Clinical Oncology. (medscape.com)
  • Treatment for osteoporosis may include adopting healthy habits and taking medicine to reduce bone loss and to build bone thickness. (healthlinkbc.ca)
  • Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q TM ), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. (bvsalud.org)
  • There is evidence that nitrogen-containing bisphosphonates can reduce the risk of breast cancer. (latinaproject.com)
  • There have been suggestions to start an aromatase inhibitor patient on bisphosphonates. (medscape.com)
  • Clearing the Patient on Bisphosphonates for Dental Procedures: When Should You Do It? (medscape.com)
  • Osteoporosis and atrial fibrillation (AF) are common in post-menopausal women. (tmu.edu.tw)
  • Patients identified as at risk for osteoporosis (including children and adolescents) should undergo preventive measures, including adequate calcium intake, vitamin D intake, and exercise. (medscape.com)
  • Risk is increased in women with lower body weight, and in those who smoke, have lost weight, have a family history of osteoporosis, have decreased physical activity, use alcohol or caffeine, and have low calcium and vitamin D intake. (aafp.org)
  • Not getting enough calcium and vitamin D may be a reason osteoporosis starts and progresses. (epnet.com)
  • You should not take oral bisphosphonates if you have esophageal conditions that delay emptying of the esophagus, or if you cannot stand or sit upright for at least 30 to 60 minutes, or have low calcium levels in your blood. (rxwiki.com)
  • They labeled calcium hydroxyapatite with fluorescent bisphosphonate, an osteoporosis drug. (newswise.com)
  • But when taken properly, calcium can go a long way toward preventing osteoporosis," says Ellis. (mainlinetoday.com)
  • The safety and efficacy of Evenity was shown in two clinical trials involving a total of more than 11,000 women with post-menopausal osteoporosis. (everydayhealth.com)
  • Conclusion: Our belief is that when assessed in combination with an algorithm of independent risk factors, measuring urinary bone turnover markers using a point of care kit may find utility in the osteoporosis clinic as an accessible, non-invasive and cost-effective alternative for the routine assessment of efficacy of bisphosphonate therapies. (eurekaselect.com)
  • Parathyroid hormone works better if you have never taken bisphosphonates. (medlineplus.gov)
  • It is now recommended that dentists screen patients for bisphosphonate use and many will not perform any significant dental procedures on patients who have taken bisphosphonates. (holtorfmed.com)
  • A 2008 literature review suggested that the use of "reminders plus education targeted to physicians and patients" can lead to increased BMD testing and greater use of osteoporosis medications. (medscape.com)
  • Osteoporosis may be caused by using injected or long-term oral medications. (healthline.com)
  • That's when we need osteoporosis medications. (mainlinetoday.com)
  • In May of this year, the Food and Drug Administration issued an analysis of bisphosphonates, suggesting-but not mandating-that patients should be on the medications for no more than five years. (mainlinetoday.com)
  • Osteoporosis affects mostly older women, but prevention starts when you are younger. (womenshealth.gov)
  • The Centers for Disease Control and Prevention (CDC) says around 20 percent of women and 5 percent of men 50 years and older have osteoporosis. (healthline.com)
  • The Pan Mersey Area Prescribing Committee recommends the prescribing of ORAL BISPHOSPHONATES (alendronic acid, ibandronic acid and risedronate sodium) for treating osteoporosis in accordance with NICE TA464. (panmerseyapc.nhs.uk)
  • According to the American Academy of Orthopaedic Surgeons (AAOS), more than half of U.S. adults over age 50 either have osteoporosis or low bone mass (osteopenia). (healthline.com)
  • Five patients with osteopenia at baseline developed osteoporosis by the end of the follow-up period, he said. (medscape.com)
  • When the drugs were introduced, we were misled by the drug companies and told to treat everyone with osteopenia-and right away, before it advanced to osteoporosis," Gordon says. (mainlinetoday.com)
  • formulations are available for patients who cannot tolerate oral bisphosphonates. (latinaproject.com)
  • In addition to net clinical benefits, bisphosphonates are much cheaper than other pharmacologic treatments and are available in generic oral and injectable formulations. (meefro.com)
  • Oral bisphosphonates are associated with gastrointestinal adverse effects, including acid reflux. (aafp.org)
  • Oral Bisphosphonates (e.g. (fpnotebook.com)
  • The U.S. Food and Drug Administration (FDA) is continuing to review data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus ( esophageal cancer ). (rxwiki.com)
  • FDA's review is ongoing and the Agency has not concluded that patients taking oral bisphosphonate drugs have an increased risk of esophageal cancer. (rxwiki.com)
  • The risk of these esophageal events is low when oral bisphosphonates are prescribed appropriately and the specific directions for use are followed by patients. (rxwiki.com)
  • Patients should talk with their healthcare professionals about the benefits and risks of taking oral bisphosphonates. (rxwiki.com)
  • Patients who take oral bisphosphonates should pay particular attention to the directions for use to minimize any potential adverse events. (rxwiki.com)
  • There is conflicting information on whether oral bisphosphonate drugs can affect your chance of developing esophageal cancer. (rxwiki.com)
  • Directions for use of the oral bisphosphonate drug should be followed carefully. (rxwiki.com)
  • Do not lie down or eat or drink anything for at least 30 to 60 minutes after taking an oral bisphosphonate drug. (rxwiki.com)
  • Talk to your healthcare professional about the benefits and risks of taking oral bisphosphonates and how long you should expect to take them. (rxwiki.com)
  • Discuss any questions or concerns about your oral bisphosphonate drug with your healthcare professional. (rxwiki.com)
  • In January 2009, a case series was published describing reports submitted to the FDA of esophageal cancer in patients prescribed oral bisphosphonates. (rxwiki.com)
  • Since then, several epidemiological studies looking at the association between oral bisphosphonates and esophageal cancer have been published, with discrepant findings. (rxwiki.com)
  • One study compared the rate of esophageal cancer in patients taking an oral bisphosphonate to patients not taking an oral bisphosphonate. (rxwiki.com)
  • This study found no increase in the risk of esophageal cancer.1 Using the same database, a second study found a doubling of the risk of esophageal cancer among patients who had 10 or more prescriptions of oral bisphosphonates, or who had taken the drugs over 3 years. (rxwiki.com)
  • Also, the prescribing information of currently available intravenous and oral bisphosphonates may provide information about ONJ. (drug-injury.com)
  • To help healthcare professionals in their efforts to understand ONJ, a non-exhaustive list of online addresses associated with independent organizations and available intravenous and oral bisphosphonates is provided as follows. (drug-injury.com)
  • Dr. Sedghizadeh DDS, the lead researcher of this study states, "We've been told that the risk with oral bisphosphonates is negligible, but it is not negligible. (holtorfmed.com)
  • We start however with the emerging issue of a possible link between bisphosphonates and the heart condition atrial fibrillation. (drug-injury.com)
  • In both studies, the rates of all atrial fibrillation (serious plus nonserious) were not significantly different between groups treated with bisphosphonate versus placebo. (drug-injury.com)
  • This October 2007 FDA item states that the agency has requested additional information, presumably from the drug companies, in order to evaluate the extent of any association between these bisphosphonates and atrial fibrillation, which is a heart rhythm disorder. (drug-injury.com)
  • Any patient who meets World Health Organization (WHO) criteria for osteoporosis should be considered for pharmacologic intervention. (medscape.com)